Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > The longer it goes before resolution

<< Previous

Bullboard Posts

Next >>

Post by MasterAlgaeon Aug 10, 2021 9:45am

252 Views

Post# 33677552

The longer it goes before resolution

of what caused the 500% liver enzyme spike the more 'complicated' (costly in delay's and potential reformulation) the outcome is likely to be.
Assuming it was booze or some other drug - that determination should be resolved fairly quickly, by now even...
Does that not make sense?

<< Previous

Bullboard Posts

Next >>

FE Battery Metals begins 2024 winter drill program